A synergic effect of gefitinib with MK-2206 (AKT inhibitor) on anti-glioma activity has been observed in vivo and in vitro by apoptosis induction (survivin downregulation) and autophagy (LC3-II accumulation) at the start of treatment (48 h), and a shift from autophagy to apoptosis (Bim increase) in a late stage of treatment (96 h) by inhibiting phosphorylation of the AKT/mTOR/S6K pathway [217]. The gene discussed is BCL2L11; the disease is central nervous system cancer.